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Abstract
Purpose In children and adolescents, dysembryoplastic
neuroepithelial tumors (DNETs) of the brain present with seizures almost 100 % of the time, potentially creating significant
long-term morbidity and disability despite the generally indolent course of the lesion. These tumors also tend to be quite
resistant to anti-epileptic drugs which, themselves, can be associated with long-term side effects and resultant disability.
Many clinicians advocate early surgical resection of these lesions, but how effective this approach is, and how aggressive
tumor removal should be, continues to be debated.
Methods We performed a systematic review of the relevant
literature to identify all reports of DNET resections in pediatric
patients published over the past 20 years. In all, over 3000
MEDLINE abstracts were reviewed, ultimately resulting in
13 studies with 185 pediatric DNET patients to review.
Results Surgical resection of the lesion was effective at improving seizures in over 98 % of patients and at achieving
long-term seizure freedom in 86 %. Surgical resection of
DNETs also appeared to be quite safe, with no reported perioperative deaths and an overall rate of postoperative
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complications of 12 %; the vast majority of these complications were transient.
Conclusions Total gross resection of the lesion was the only
factor statistically correlated with long-term seizure freedom
(r=0.63, p=0.03). However, data remain lacking regarding
whether this translates into more extensive procedures—like
brain mapping and partial lobectomies—being any more effective than simple lesionectomies alone. Further research is
clearly needed to address this and other crucial questions.
Keywords DNET . Pediatric brain tumors . Seizure surgery .
Epilepsy

Introduction
In North America, no other solid tumor is as common or
causes more deaths in children and adolescents than cancers
of the brain [16, 26, 84], with roughly three quarters of patients presenting at less than 15 years of age [12]. The prognosis for long-term survival is much better in children than in
adults, with up to half of pediatric brain tumor patients surviving long term [25]. The main reason for this enhanced survival
is that children and adolescents tend to have lower-grade lesions [79, 95, 101]. Long-term survival is not without problems, however, with many pediatric brain tumor survivors
continuing to suffer from significant morbidity [44, 63, 76,
90, 94, 108] and, sometimes, early death [90]. Among the
more common long-term sequelae of brain tumors and their
treatment in children are seizures, which can be quite disabling and, at times, life-threatening in themselves [90, 3,
56, 66, 67, 85, 87, 104, 106, 110]. In one study, seizures were
the dominant predictor of disability in long-term brain tumor
survivors [66, 67]. Seizures even increase a pediatric brain
tumor survivor’s risk of suicide into adulthood [13]. Of the
epileptogenic tumors, low-grade lesions comprise the
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majority [86]. Of these, dysembryoplastic neuroepithelial tumors (DNETs) present with seizures almost 100 % of the time
[1, 65, 73, 97, 104].
Because these tumors typically are slow-growing and noninvasive, the primary objective of DNET management in most
cases is control, if not eradication, of seizures. Because tumorassociated seizures tend to be more resistant to anti-epileptic
drugs (AEDs) than idiopathic seizures [57, 98] and the longterm use of AEDs is not without significant risks in itself [22,
23, 56, 66, 68, 100, 107], including wide-ranging adverse
effects on cognitive function and development [56, 100], this
typically necessitates surgery to resect as much of the tumor as
possible [21, 70, 73, 78, 89, 97, 104]. In addition, several
studies have shown that radical removal of an epileptogenic
brain tumor is a strong, and likely the strongest, predictor of
seizure freedom [39]. On the other hand, especially among
younger children, the risks of surgery cannot be discounted
as, in addition to the risk of perioperative mortality, surgery
also can adversely affect neurological development and function [38].
The primary purpose of this paper is to extensively and
systematically review and analyze the literature on surgical
outcomes in pediatric patients with DNETs, specifically
looking at perioperative complications and mortality, shortand long-term seizure control, and short- and long-term survival.

Search methods
The main search objective was to identify all papers involving
pediatric patients with DNETs undergoing surgical resection
over the past 20 years (1994–2014), in which the following
information was available either for the entire sample or for
individual patients (for papers in which patients with a range
of tumor types are represented): number of patients with a
DNET, (mean) age at the time of seizure onset, (mean) age
at the time of surgery, age range, type of seizure, type of
surgery, location of the lesion, number of subjects in which
complete resection was achieved, number with immediate
postoperative complications including recurrent/persistent seizures, (mean) length of follow-up, long-term survival, longterm neurological sequelae, the number with seizures at final
follow-up, and final Engel rating [27]. The period 1994 to
2014 was selected because it was felt that older papers reported the results of studies with considerably less robust methodology and because most papers prior to 1995 did not report
many of the specific variables of interest listed above.
All the included papers were identified via an extensive
search of the PubMed database, using the following search
terms: dysembryoplastic neuroepithelial tumor (n = 425),
DNET (n=193), neuroglial tumor (n=401), neuroglial tumor
and seizure (n=1574), and neuroglial tumor and surgery (n=
871). Of these terms, only those with n ≤2000 were reviewed,
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because of the lack of specificity of longer lists. A total of 33
papers were identified in which surgery was conducted on
children with DNETs, and the above-noted data were available in 24 [5, 9, 10, 15, 17, 21, 31, 35, 36, 47, 48, 51, 52, 54,
55, 58, 59, 70, 73, 75, 80, 89, 97, 105]. However, of these,
only seven studies had pediatric DNET patients exclusively
[9, 30, 58, 70, 73, 89, 97], two had both adult and pediatric
patients, but individualized data [17, 59], and an additional
four papers [5, 15, 47, 51] had individual data on DNET
patients among patients with other lesions that allowed for
the extraction of almost all of the variables of interest.
Analysis consisted of calculating means and percentages,
Pearson correlation coefficients to identify the strength of correlation between study means of continuous variables, and
likelihood ratios and Pearson χ2 analyses to examine categorical variables. Where indicated, a p value of 0.05 or less was
considered indicative of a statistically significant intergroup
difference or correlation. Correlation strength was categorized
as weak (r<0.40), moderate (0.40–0.69), or strong (r≥0.70)
as indicated in the review of Taylor [102].

Search results and analysis
Table 1 lists the 13 studies identified in which data of interest
were available for patients with dysembryoplastic
neuroepithelial tumors (DNETs), including six papers specific
to pediatric DNET tumors for which totals and means are
presented [9, 58, 70, 73, 89, 97] and seven papers with data
presented for individual DNET patients from which totals and
means could be calculated [5, 15, 17, 30, 47, 51, 58]. These 13
studies encompass 185 patients, of mean age 9.4 years, with
individual patients ranging in age from 0.5 to 21 years. All the
series were small, one paper reporting a single case [47] and
only four having 20 or more patients [9, 58, 70, 74]. The
largest study was that reported by Bilginer et al. with 29 pediatric DNET patients [9]. The mean sample size across the 13
series papers was 14.3. The mean duration of seizures prior to
surgical resection of the underlying DNET across the 13 studies was 3.2 years but ranged widely from 4 and 7 months [15,
47] to 7 years [70, 97]. Complex partial seizures accounted for
86.4 % of seizures, ranging from 55.6 % [89] to 100 % [5, 30,
58]. The mean percentage of DNETs located within a temporal lobe across the 13 studies was 67.8 %, though this ranged
quite broadly from 38.5 % [73] and 42.9 % [30] to 100 % [15].
Considering subjects individually, rather than assessing study
means, the overall weighted percentage of patients presenting
with complex partial seizures was 81.3 % and the percentage
with a temporal lobe lesion 63.8 %. Gross total resection was
achieved in 83.3 % of patients, the percentage lowered by a
single study in which gross total resection was achieved in
only 11 of 26 [73].
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In three of the studies, lesionectomies alone were utilized to
resect the lesion, with data on the number of total resections
available, accounting for 32 patients. Of this number of procedures, 27 yielded a total gross resection (84.4 %) versus 64
of 67 patients in whom lesionectomy was combined with further resection (95.5 %); hence, the odds of an incomplete
resection (OR) was 3.49 (95 % confidence interval=0.78,
15.51, p=0.10).
Over the 13 studies, long-term postoperative freedom from
seizures was achieved in 85.9 % of patients, at a mean followup of 63.3 months (5.25 years). The percentage of patients
achieving seizure freedom in the 12 years from 1994 through
2006 was 81.6 versus 91.3 % in studies published from 2007
onward; however, this difference failed to achieve statistical
significance (t=1.20, df=11, p=0.26). Although a moderate
direct correlation was noted between the year of paper publication and the percentage seizure freedom, this also failed to
achieve statistical significance (r=0.45, p=0.23). On the other
hand, the percentage of patients achieving seizure freedom in
a given study was both moderately and statistically correlated
with the percentage of procedures resulting in gross total resection (r=0.63, p=0.03), but not with mean patient age
(r=-0.45, p=0.12) or mean duration of follow-up (r=0.20,
p=0.51). No correlation at all was noted between the percentage of subjects achieving seizure freedom and any of the three
variables mean duration of seizures prior to surgery
(r =−0.007, p =0.98), percentage of patients with complex partial seizures (r=0.063, p =0.87), or percentage
of patients with a temporal lobe lesion (r=0.052, p =0.087).
In the seven studies in which sufficient individual subject
data were available, there were 68 gross total resections,
resulting in long-term seizure freedom in 62 patients
(91.2 %), and 3 subtotal resections, all having Engel stage
III outcomes, so that the likelihood of a poor outcome was
more than 13 times higher (LR=13.4; p<0.001) with a
subtotal resection. In those same seven studies, 45 of 75
patients underwent a lesionectomy alone and 30 a
lesionectomy plus some additional resection, with or
without mapping. Of the 45 who underwent lesionectomy
alone, 40 (88.9 %) achieve total seizure freedom versus 25 or
30 (83.3 %) among those in whom some additional resection
was performed (Pearson χ 2 = 0.48, p = 0.49). By age
group, postoperative seizure freedom was achieved in
10 of 11 (90.9 %) of children under age 6, 31 of 35
(88.6 %) children from age 6 up to, but not including
13, and 24 of 29 (82.8 %) of adolescents of 13 years or
older, a seemingly downward trend that was not statistically significant (χ2 =0.67, p=0.71). The mean duration of follow-up over these seven studies with individualized data was 40.3 months. Comparing seizure-free rates
between patients with a follow-up duration below and above
that mean again revealed no significant difference (89.1 vs.
82.2 %, χ2 =0.63, p=0.43).
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Similarly, neither duration of seizures (χ2 =2.19, df=3,
p=0.54) nor temporal location of the tumor (χ2 =1.44, df=1,
p=0.23) was associated with seizure freedom. Since all but
one of the patients with seizure-type data had suffered from
complex partial seizures, no individualized data analysis for
seizure type was performed.
An improvement in seizures was documented in 183 of 185
patients across the ten studies (98.9 %). There were no immediate or late deaths over the course of reported follow-up, and
the perioperative complication rate, adjusted for missing data,
was just 11.9 %. Postoperative tumor recurrence was reported
in two patients, including one whose seizures recurred with
tumor recurrence and then improved but did not fully abate
following a second resection [30].

Discussion
DNETs, which typically become manifest during childhood,
adolescence, or young adulthood, represent only a small percentage of CNS tumors in either youths or adults [40].
However, these tumors, which typically occur in the temporal
lobes [64], are almost always associated with seizures.
Together with gangliogliomas and focal cortical dysplasia
(FCD), they account for the lion’s share of surgically amenable epileptic brain lesions [43]. Consequently, they comprise a
disproportionate percentage of tumor-associated epilepsy
cases, especially in children [1, 50, 92, 93, 97, 104, 109].
The reason for the almost ubiquitous presence of seizures with
brain tumors like DNETs and gangliogliomas versus much
lower rates seen with others, like low-grade gliomas, is not
entirely understood [87, 88, 91, 107], although several conjectures have been made, including differential alterations in
regional metabolism and pH; immunologic activity; disordered neuronal function; altered vascular supply and permeability; the release of altered tumoral amino acids, proteins,
and enzymes; and abnormal protein transport and binding to
receptors [1, 14, 87, 91, 93, 107, 114]. Even genetic predispositions for tumor-related seizures have been postulated [8,
107]. To date, all that can be said with confidence is that the
cause of tumor-induced seizures is almost certainly multifactorial [114] and beyond the mere physical size of the tumor
itself [60].
The risks of surgical resection of an epileptogenic but otherwise Bbenign^ brain tumor, like a DNET, must be weighed
against the possible consequences of managing seizures conservatively, due to their potential to inflict significant neurological and cognitive damage, despite favorable rates of survival [28, 66, 67]. In several studies, preoperative cognitive
function in pediatric patients with glioneuronal tumors tended
to be low average to average and associated with a variety of
cognitive deficits, including problems with speech and memory, and delay to meet developmental milestones [24, 29, 32,
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34, 82]. Since DNETs tend to be extremely resistant to AED
therapy, pharmaceutical control of seizures typically is incomplete [9, 17, 19, 58, 73, 80]. This places patients at risk for
continued brain injury and worsening neurocognitive function, prompting many authors to argue for surgical resection
of the lesions as soon as possible in most cases [10, 11, 19, 34,
37, 47, 51, 99, 113, 115]. Among the various specific arguments given for early surgical resection of glioneuronal tumors, including DNETS, are the optimization of seizure control [21, 75, 89, 105, 113, 115, 116]; the optimization of brain
development [10, 11, 17, 19]; avoiding or at least minimizing
the long-term risks of AEDs [22, 53, 66, 68, 96, 107], especially in children and those who may require chemotherapy to
control tumor growth [49]; and reducing the risk, albeit low, of
later, catastrophic malignant change [2, 20, 41, 61, 71, 72, 81].
Brain surgery is certainly not without its own potential
consequences and risks, however, including the prospect of
postoperative mortality and worsening seizures and of immediate postoperative neurological deficits and cognitive decline. In their retrospective review of 223 patients 19 years
old and under who underwent a combined 229 surgical resections of non-epileptogenic brain tumors, Hardesty et al. identified an incidence of new, postoperative seizures of 7.4 %
[42]. On the other hand, almost all were single events that
resolved without the need for long-term anti-epileptic drugs
(AEDs). Supratentorial tumors, patient age less than 2 years,
and the presence of significant postoperative hyponatremia
were independent risk factors for new seizures [42].
Presumably, then, these same risk factors of young age and
postoperative serum sodium imbalance would at least slightly
predispose patients with epileptogenic tumors to having continued or worsened seizures postoperatively. However, worsened seizures postoperatively were reported uncommonly in
our review of 13 published studies/series, and the vast majority was transient and controlled prior to hospital discharge.
Moreover, Steinbok et al. [99], in their retrospective analysis
of 116 pediatric patients under age 3 drawn from eight centers
across Canada (mean age at first surgery 15.8 months; range
1–35 months), identified only one surgical death. The most
common surgical complications over 151 operations were infection (17) and aseptic meningitis (13). Moreover, more than
1 year postoperatively, 72 (67.3 %) were seizure free and more
than 90 % significantly improved. In addition, cognitive development improved in 55.3 % postoperatively.
In the medical literature, the rate of seizure freedom in
series with either adults alone or adults plus children has varied widely for DNETs, from as low as 52.4 and 53.3 % [33,
83] to as high as 90 and 100 % [89, 58]. In the current review,
we chose to look exclusively at DNETs operated upon during
the pediatric years, with one patient aged 21 and all others 19
or younger, to as young as 5 months of age. Overall, in this age
group, long-term freedom from seizures was achieved in almost 86 % (85.9 %) and some improvement in 99 % (all but
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two of 185 patients). Moreover, there were no deaths, and the
rate of postoperative complications, the vast majority transient
neurological deficits, was only 12 %. The only variable either
correlated with seizure freedom rate at a study mean level or
associated with seizure freedom at an individual level was
degree of tumor resection, with subtotal resections virtually
always associated with either the persistence or recurrence of
seizures. Patient age was not associated, and neither was
whether or not lesionectomy alone or lesionectomy plus some
additional resection was performed. These results are congruent with those of a recently published retrospective analysis of
29 children undergoing resection of glioneuronal tumors, in
which the rate of seizure freedom 12 months after surgery was
94 % in those in whom gross total resection was achieved
versus just 54 % in those in which it was not (p<0.05) [80];
unfortunately, only 13 of the patients were determined to have
a DNET, versus 16 with a ganglioglioma, limiting comparisons against our own results. With even more limitations, our
results are also consistent with a larger series of 332 patients
(mean age 39.3 years, range 16–95) with low-grade gliomas
who underwent operative resections for a variety of tumors, in
whom seizure control again was far more likely to be achieved
after gross total resection than after subtotal resection or biopsy alone (odds ratio 16, 95 % confidence interval 2.2–124, p=
0.0064) [18]. One further characteristic that hampers these
afore-mentioned studies to some degree is the disproportionate number of complete to incomplete resections. The same is
not true of the one series of 26 pediatric patients with DNETs
reported by Nolan et al., in which the distribution of gross
complete to incomplete resections was fairly evenly split (12
complete, 14 incomplete resections) [73]; in this series, all
nine children who had no detectable tumor on postoperative
imaging were seizure free at 12 months, with only one relapsing at final follow-up, versus an approximately 50 % rate of
seizure freedom in the remainder (p=0.02).
Given that completeness of tumor resection seems to be a
determinant of seizure outcomes, the question arises: is it better to do more than just a simple lesionectomy, either via brain
mapping to detect epileptogenic foci apart from the tumor
itself, or more extensive resections? Over the years, attempts
have repeatedly been made to optimize the resection of epileptogenic lesions, both by better delineating their margins
and by enhancing the identification of extra-tumoral epileptogenic tissue, using intraoperative tools like electrocorticography (ECoG) to identify potential seizure-inducing tissue irregularities like FCD [4, 7, 28, 35, 46, 58, 75, 89, 111, 112]. This
has led to considerable speculation with respect to the relative
benefits and safety of performing epilepsy surgery rather than
just lesionectomies in patients with tumor-induced seizures
[62], even though surgeons have been utilizing additional surgical steps like lobectomy, amygdalohippocampectomy, and,
in extreme cases, hemispherotomy for decades [5, 9, 10, 15,
35, 45, 48, 51, 55, 75, 77, 80, 89, 97, 103, 105]. To date,
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almost no direct empirical comparisons have been undertaken.
In perhaps the most methodologically sound study, Gelinas
et al. retrospectively compared 34 patients who underwent
ECoG-aided epilepsy surgery and 33 patients who had undergone simple lesionectomy without ECoG, all between the
ages of 3 months and 16 years, in Vancouver, Canada [35].
One year following surgery, roughly 80 % of patients in each
group were seizure free. However, long-term data trended
toward improved seizure freedom in patients in the ECoG
group, with 79 versus 61 % patients still seizure free at a mean
5.8 years of follow-up (p=0.08). The investigators also noted
no increase in neurological morbidity among patients who had
undergone the more extensive ECoG-guided cortical resection
and that these patients were less likely to require repeat epilepsy surgery [35]. In another smaller retrospective analysis
reported by Chan et al. [17], whereas 10 of 12 pediatric DNET
patients undergoing a temporal lobectomy achieved seizure
freedom, such freedom was achieved in only two of six who
had a lesionectomy alone, a difference that, using Pearson χ2
analysis, is statistically significant (χ2 =4.5, p=0.03) despite
the small numbers. These two studies aside, how effective
such tools and approaches are in terms of seizure outcomes,
especially in children, remains largely unstudied and, hence,
unclear.
The question therefore should no longer be whether or not
surgery is indicated in children with an epileptogenic neuroglial tumor like DNET or ganglioglioma, or even at what age
such surgery begins to be safe [99, 69], but how surgery
should be performed and how aggressive one should be to
remove all tumor and/or epileptogenic tissues. In some children, because of the location of the tumor, both in terms of
accessibility and proximity to high-function areas of the brain,
the child’s overall health status, and perhaps other issues as
well, total resection is infeasible. However, even in patients in
whom only partial resection was achieved, long-term seizurefree rates have exceeded 50 % [73, 80]. More importantly, in
this review of 185 pediatric DNET cases spanning 13 studies
and two decades, only two patients failed to improve, and
there were no perioperative deaths. In addition, in patients in
whom seizure control is initially attained but then lost, repeat
surgery appears to be of value. For example, among 106 children (mean age 13.5 years at surgery) who underwent temporal lobe resections for either low-grade tumor or vascularanomaly-induced epilepsy at The Hospital for Sick Children
in Toronto, Canada, between 1983 and 2003, 12 ultimately
required a second temporal lobe procedure for intractable recurrent seizures; of these, seven returned to a seizure-free state
[6].
Our analysis has admitted limitations, starting with the
non-random nature of patient selection which, technically,
prohibits the use of certain statistical tests. Note also that the
wide range in sample sizes generates weighting issues, in that
a report with a single patient was treated statistically the same
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as series with more than 20. It was for this reason that we
attempted to identify as much individual subject data as possible. In fact, this resulted in almost 100 cases being available
for analysis, among whom the same association between completeness of resection and long-term seizure freedom was apparent, albeit merely approaching statistical significance.
Moreover, we do not claim that our results are empirically
definitive; they merely illustrate the inadequacy of current
series, all too small to allow for most of the statistical manipulations that we have attempted, and the need for further research, preferably across multiple centers to allow for more
adequate patient numbers.

Conclusions
From this review of 13 studies on DNET resections in children
and adolescents, it is clear that surgical resection of the lesion
is effective at improving seizures in almost all patients and at
achieving long-term seizure freedom in the vast majority.
Surgical resection of DNETs also appears to be very safe in
children, in terms of both mortality and long-term surgeryrelated morbidity. Total resection of the lesion appears to be
the best predictor of seizure freedom. However, data are lacking on whether this translates into more extensive procedures—like brain mapping and partial lobectomy—being
any more effective than simple lesionectomy alone. Further
prospective research, preferably involving multiple centers to
generate more adequate subject numbers, is clearly indicated.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
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